Patients with type 2 diabetes are missing out on the “compelling” cardiorenal benefits of SGLT2 inhibitors because different specialist groups are nitpicking over minor discrepancies in guidelines, experts say. Urgent action is needed on clearer messaging because only a small proportion of patients with diabetes and cardiovascular risk, heart failure or renal disease are currently ...
Cardiologists urged to act on underuse of cardiorenal drugs in diabetes patients
By Michael Woodhead
19 Nov 2020